ScholarLens Back to search
2022•Clinical Lymphoma Myeloma & LeukemiaRequires access

Poster: CLL-532 Changes in Proteome of CLL (Chronic Lymphocytic Leukemia) Lymphocytes During Investigator-Initiated Trial of Ibrutinib Alone and in Combination With Venetoclax in Treatment-Naïve Patients With CLL

Natalia Timofeeva, Nitin Jain, Ehsan Irajizad, Burcu Aslan, Hiroyuki Katayama, Yining Cai, Mary Ayres, LaKesla R. Iles, Jody V. Vykoukal, Jennifer B. Dennison, Samir Hanash, William G. Wierda, Varsha Gandhi

Open publisher page 0 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Ibrutinib, Venetoclax, Chronic lymphocytic leukemia, Medicine, Oncology, Internal medicine, Bruton's tyrosine kinase, Leukemia

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Poster: CLL-532 Changes in Proteome of CLL (Chronic Lymphocytic Leukemia) Lymphocytes During Investigator-Initiated Trial of Ibrutinib Alone and in Combination With Venetoclax in Treatment-Naïve Patients With CLL — Research Paper | ScholarLens